A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme — SHORTEN

Fabry's Disease Clinical Trial

Official title:
A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion

Status Recruiting

Clinical Trial Summary

This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.

Clinical Trial Description

The total duration will be up to 6 months ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06019728
Study type	Interventional
Source	Sanofi
Contact	Trial Transparency email recommended (Toll free for US & Canada)
Phone	800-633-1610
Email	Contact-US@sanofi.com
Status	Recruiting
Phase	Phase 4
Start date	November 10, 2023
Completion date	October 6, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01178164` - Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains	N/A
Terminated	`NCT02582294` - Fabry's Disease and Pregnancy (PREFAB)
Recruiting	`NCT02469181` - Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy (RECAFTURE Trial)
Completed	`NCT02798458` - Evaluation of the Gastrointestinal Manifestation of Fabry's Disease	N/A
Completed	`NCT00001491` - Analysis of the Nervous System in Patients With Fabry's Disease	N/A
Completed	`NCT02450604` - Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain	N/A
Recruiting	`NCT04847713` - Early Detection and Follow-Up of Patients With Fabry's Disease